These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

533 related items for PubMed ID: 18046027

  • 1. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
    McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH, TPL102357 Study Group.
    N Engl J Med; 2007 Nov 29; 357(22):2227-36. PubMed ID: 18046027
    [Abstract] [Full Text] [Related]

  • 2. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D.
    Gastroenterology; 2014 Feb 29; 146(2):442-52.e1. PubMed ID: 24126097
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK.
    Lancet; 2015 Oct 24; 386(10004):1649-58. PubMed ID: 26231455
    [Abstract] [Full Text] [Related]

  • 5. Eltrombopag in thrombocytopenia.
    Lawson A.
    N Engl J Med; 2008 Mar 06; 358(10):1072; author reply 1072-3. PubMed ID: 18322290
    [No Abstract] [Full Text] [Related]

  • 6. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
    Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM.
    N Engl J Med; 2007 Nov 29; 357(22):2237-47. PubMed ID: 18046028
    [Abstract] [Full Text] [Related]

  • 7. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK.
    Lancet Haematol; 2015 Aug 29; 2(8):e315-25. PubMed ID: 26688484
    [Abstract] [Full Text] [Related]

  • 8. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M.
    Lancet; 2009 Feb 21; 373(9664):641-8. PubMed ID: 19231632
    [Abstract] [Full Text] [Related]

  • 9. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, Anagnostopoulos A, Brenner B, Denzlinger C, Rossi G, Nagler A, Garcia-Delgado R, Portella MSO, Zhu Z, Selleslag D.
    Lancet Haematol; 2018 Jan 21; 5(1):e34-e43. PubMed ID: 29241762
    [Abstract] [Full Text] [Related]

  • 10. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB.
    Lancet; 2011 Jan 29; 377(9763):393-402. PubMed ID: 20739054
    [Abstract] [Full Text] [Related]

  • 11. Eltrombopag in chronic hepatitis C.
    Mihăilă RG, Cipăian RC.
    World J Gastroenterol; 2014 Sep 21; 20(35):12517-21. PubMed ID: 25253952
    [Abstract] [Full Text] [Related]

  • 12. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.
    Lancet Haematol; 2015 Oct 21; 2(10):e417-26. PubMed ID: 26686043
    [Abstract] [Full Text] [Related]

  • 13. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R.
    Lancet Haematol; 2017 Mar 21; 4(3):e127-e136. PubMed ID: 28162984
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
    Kawaguchi T, Komori A, Seike M, Fujiyama S, Watanabe H, Tanaka M, Sakisaka S, Nakamuta M, Sasaki Y, Oketani M, Hattori T, Katsura K, Sata M.
    J Gastroenterol; 2012 Dec 21; 47(12):1342-51. PubMed ID: 22674141
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial.
    Arnold DM, Heddle NM, Cook RJ, Hsia C, Blostein M, Jamula E, Sholzberg M, Lin Y, Kassis J, Larratt L, Tinmouth A, Amini S, Schipperus M, Lim W, Vishnu P, Warner M, Carruthers J, Li N, Lane S, Kelton JG.
    Lancet Haematol; 2020 Sep 21; 7(9):e640-e648. PubMed ID: 32853584
    [Abstract] [Full Text] [Related]

  • 19. Eltrombopag in patients with chronic liver disease.
    Giannini EG, Afdhal NH.
    Expert Opin Pharmacother; 2013 Apr 21; 14(5):669-78. PubMed ID: 23452139
    [Abstract] [Full Text] [Related]

  • 20. Molecule of the month. Eltrombopag.
    Drug News Perspect; 2008 Apr 21; 21(6):344. PubMed ID: 18836592
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.